What China’s Latest Drug Negotiations Mean for Global Pharma Companies

Posted by Crystal Lam on Wed, Jan 22, 2020

Sonia Yan and Daniel Blessing co-authored this blog post with Crystal Lam.

China’s National Healthcare Security Administration (NHSA) recently released the outcomes of its 2019 National Reimbursed Drug List (NRDL) negotiations: 70 of 119 new therapies were successfully listed. This record outcome more than doubled the number of therapies reimbursed through China’s negotiation pathway, which was formally implemented in 2017.


>
Read More

International Customer Segmentation and Targeting: An Implementation Case Study

Posted by Didier Chicheportiche on Wed, Dec 13, 2017

Simon Stirrup co-wrote this blog post with Didier Chicheportiche

This blog post is the final in a three-part series on why pharmaceutical companies should develop and implement an international customer segmentation and targeting strategy, what it takes to get started, and how one company has found success in overcoming common pitfalls.

In the first post in this series, we looked at the challenges inherent in translating a philosophy of customer engagement into a practical segmentation and targeting approach that works at the global level. In the second post in this series, we shared best practices for building and implementing an international strategy that enables the right activities to be delivered to the right customers at the right time. In this installment, we’ll look at how one company successfully harmonized its tools and processes to enable a consistent—but also flexible—sales management strategy across global markets.


>
Read More